NATICK, Mass.–(BUSINESS WIRE)–AutoIVF Inc., a pioneering fertility care company, has closed an equity investment round, led by Vitrolife Group, with participation from new investors including Alpha Edison and IVF industry stalwarts.  AutoIVF’s flagship product, OvaReady, is a groundbreaking automated system that simplifies and enhances egg retrieval and preparation in the current IVF process and supports decentralizing the egg retrieval process outside traditional IVF laboratory settings.

According to the World Health Organization (WHO), one in six people globally will experience infertility at some point in their lives. This underscores the urgent need for accessible, high-quality fertility care worldwide.

Led by CEO Ravi Kapur Ph.D., FAIMBE, AutoIVF’s founding and leadership team brings more than 200 years of combined experience in IVF, microfluidics, and reproductive health, driving its mission to democratize fertility care, expand global access, and reimagine the future of assisted reproductive technologies.

“The National Institutes of Health’s ongoing support through their Small Business Innovation Research Awards has validated the strength of our technology and our rigorous clinical approach. This foundation has enabled us to demonstrate the real-world impact of OvaReady. With this new investment and partnership, we’re excited to accelerate our path to market and explore collaborations that can expand access, scale innovation, and create lasting value across the reproductive health ecosystem,” said Ravi Kapur, CEO of AutoIVF.

‘’This investment and partnership mark another step in our corporate strategy to build an end-to-end platform that connects products and services across the entire IVF workflow. By continuing to automate the IVF process we will enable safe, efficient and effective fertility care,” says Bronwyn Brophy O’Connor, CEO of the Vitrolife Group.

Erin Schardt, SVP and GM North America at Vitrolife Group, will join AutoIVF’s Board of Directors.

About AutoIVF

AutoIVF is pioneering a new era in fertility care by making in vitro fertilization (IVF) more accessible, affordable, and efficient. Our flagship technology, OvaReady, is a groundbreaking automated system that simplifies and enhances egg collection and preparation for the current IVF process, while enabling high-quality fertility services to be delivered outside traditional IVF labs. Backed by a team with over 200 years of combined expertise in IVF, women’s health, microfluidics, and cryobiology, we are committed to transforming the delivery of fertility treatment. The Company has raised over $16 million in public and private funding, including major National Institute of Health SBIR awards.

About Vitrolife Group

Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,100 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.

Contacts

Ravi Kapur, info@autoivf.com

(c)2025 Business Wire, Inc., All rights reserved.